A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer

National Cheng Kung University Hospital /ID# 234267, Tainan City

National Cancer Center /ID# 240169, Goyang

Seoul National University Bundang Hospital /ID# 234274, Seongnam

Duke Cancer Center /ID# 207547, Durham

University of Alabama at Birmingham - Main /ID# 207295, Birmingham

Tennessee Oncology, PLLC /ID# 207175, Nashville

University of Kentucky Chandler Medical Center /ID# 208217, Lexington

The Ohio State University /ID# 207552, Columbus

UH Cleveland Medical Center /ID# 207561, Cleveland

Henry Ford Hospital /ID# 233539, Detroit

University of Iowa Hospitals and Clinics /ID# 207560, Iowa City

Washington University-School of Medicine /ID# 207168, St Louis

Highlands Oncology Group, PA /ID# 207176, Springdale

NEXT Oncology /ID# 207167, San Antonio

University of California, Davis Comprehensive Cancer Center /ID# 207548, Sacramento

University of Washington /ID# 207557, Seattle

Yale School of Medicine /ID# 207559, New Haven

Massachusetts General Hospital /ID# 207549, Boston

Dana-Farber Cancer Institute /ID# 213032, Boston

University of Michigan Comprehensive Cancer Center /ID# 207177, Ann Arbor

Memorial Sloan Kettering Cancer Center-Koch Center /ID# 208216, New York

Vanderbilt Ingram Cancer Center /ID# 207551, Nashville

University of Utah /ID# 207553, Salt Lake City

Univ of Wisconsin Hosp/Clinics /ID# 207556, Madison

National Cancer Center Hospital East /ID# 230943, Kashiwa-shi

National Hospital Organization Shikoku Cancer Center /ID# 229737, Matsuyama

Hokkaido Cancer Center /ID# 229101, Sapporo

Shizuoka Cancer Center /ID# 230911, Sunto-gun

Wakayama Medical University Hospital /ID# 229111, Wakayama

Yonsei University Health System Severance Hospital /ID# 239515, Seoul

Seoul National University Hospital /ID# 234272, Seoul

Asan Medical Center /ID# 234273, Seoul